QR-koodi

The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer

As an antibody-drug conjugate (ADC), disitamab vedotin (RC48) is a promising treatment targeting ERBB2 for locally advanced and metastatic bladder cancer (BLCA). However, the subtype heterogeneity of muscle-invasive bladder cancer (MIBC) often leads to different therapeutic outcomes. In our study, w...

Täydet tiedot

Tallennettuna:
Päätekijät: Jingxian Li, Kun Shan, Wei Huang, Qiang Su, Yuanjiong Qi, Zhihong Zhang, Jianqiang Zhu, E. Du
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2025-01-01
Sarja:Frontiers in Immunology
Aiheet:
RC48-ADC
MIBC
artesunate
molecular subtypes
targeted therapy
Linkit:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1432586/full
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia